YU40202A - Novi derivati tiazolidindiona kao antidijabetički agensi - Google Patents

Novi derivati tiazolidindiona kao antidijabetički agensi

Info

Publication number
YU40202A
YU40202A YU40202A YUP40202A YU40202A YU 40202 A YU40202 A YU 40202A YU 40202 A YU40202 A YU 40202A YU P40202 A YUP40202 A YU P40202A YU 40202 A YU40202 A YU 40202A
Authority
YU
Yugoslavia
Prior art keywords
antidiabetic agents
thiazolidinedione derivatives
antidiabetic
utilization
compounds
Prior art date
Application number
YU40202A
Other languages
English (en)
Inventor
Mancini Marisabel Mourelle
Nieto Juan Carlos Del Castillo
Amat Elisabet De Ramon
Original Assignee
Laboratorios Vita S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Vita S.A. filed Critical Laboratorios Vita S.A.
Publication of YU40202A publication Critical patent/YU40202A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dati pronalazak se odnosi na jedinjenja opšte formule (I), na njihove moguće farmaceutski prihvatljive soli i tautomerne oblike. Dati pronalazak se takodje odnosi na postupak za njihovu proizvodnju i na njihovu upotrebu kao antidijabetika i hipoglikemičnih agenasa, samih ili u kombinaciji sa ostalim antidijabetičkim agensima, kao što su sulfoniluree ili biguanidi, kao i za lečenje komplikacija povezanih sa otpornošću na insulin, kao što je hipertenzija, hiperurikemija ili ostala kardiovaskularna, metabolička, endokrina stanja, ili ostala stanja povezana sa dijabetesom.[The invention relates to compounds of general formula (I), to their possible pharmaceutically acceptable salts and tautomeric forms. The invention also relates to a method for obtaining said compounds and to their utilization as antidiabetic and hypolipidemic agents, by themselves or combined with other antidiabetic agents such as sulfonylureas or biguanides, as well as to their utilization in the treatment of complications associated with insulin resistance such as hypertension, hyperuricemia or other cardiovascular, metabolic and endocrine disorders or other disorders associated with diabetes.
YU40202A 1999-11-18 2000-11-15 Novi derivati tiazolidindiona kao antidijabetički agensi YU40202A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009902533A ES2156574B1 (es) 1999-11-18 1999-11-18 Nuevos derivados de tiazolidindiona como agentes antidiabeticos

Publications (1)

Publication Number Publication Date
YU40202A true YU40202A (sh) 2006-01-16

Family

ID=8310628

Family Applications (1)

Application Number Title Priority Date Filing Date
YU40202A YU40202A (sh) 1999-11-18 2000-11-15 Novi derivati tiazolidindiona kao antidijabetički agensi

Country Status (37)

Country Link
US (1) US7001910B1 (sh)
EP (1) EP1231211B1 (sh)
JP (1) JP2003514817A (sh)
KR (1) KR100518110B1 (sh)
CN (1) CN1159314C (sh)
AP (1) AP1330A (sh)
AR (1) AR031080A1 (sh)
AT (1) ATE241622T1 (sh)
AU (1) AU770045B2 (sh)
BG (1) BG106699A (sh)
BR (1) BR0015613A (sh)
CA (1) CA2391913A1 (sh)
CO (1) CO5261560A1 (sh)
CR (1) CR6640A (sh)
CZ (1) CZ20021654A3 (sh)
DE (1) DE60003072T2 (sh)
DK (1) DK1231211T3 (sh)
EA (1) EA004301B1 (sh)
EE (1) EE200200254A (sh)
ES (2) ES2156574B1 (sh)
GE (1) GEP20043240B (sh)
HR (1) HRP20020426A2 (sh)
HU (1) HUP0203478A2 (sh)
IL (1) IL149634A0 (sh)
IS (1) IS2014B (sh)
MA (1) MA26844A1 (sh)
MX (1) MXPA02005011A (sh)
NO (2) NO20022336L (sh)
NZ (1) NZ519264A (sh)
OA (1) OA12089A (sh)
PE (1) PE20010858A1 (sh)
PL (1) PL354877A1 (sh)
PT (1) PT1231211E (sh)
SK (1) SK6752002A3 (sh)
WO (1) WO2001036416A1 (sh)
YU (1) YU40202A (sh)
ZA (1) ZA200203906B (sh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174748B1 (es) * 2001-01-31 2003-09-16 Vita Lab Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos.
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
US7713983B2 (en) 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US20050014732A1 (en) * 2003-03-14 2005-01-20 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-diabetic agent
US8283354B2 (en) 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
CZ297347B6 (cs) * 2004-09-21 2006-11-15 Zentiva, A. S. Zpusob prípravy rosiglitazonu
JP5546372B2 (ja) * 2010-06-30 2014-07-09 積水メディカル株式会社 ベンジルヒダントイン化合物の製造法
WO2016184895A1 (en) 2015-05-18 2016-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Means for detecting or measuring a biological activity of a botulinum toxin
US10689374B1 (en) 2019-07-12 2020-06-23 United Arab Emirates University Pyrimidine-thiazolidinone derivatives
US10702525B1 (en) * 2019-09-04 2020-07-07 United Arab Emirates University Pyrimidine derivatives as anti-diabetic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
EE200200254A (et) 2003-06-16
MA26844A1 (fr) 2004-12-20
KR100518110B1 (ko) 2005-10-04
OA12089A (en) 2006-05-04
ATE241622T1 (de) 2003-06-15
JP2003514817A (ja) 2003-04-22
WO2001036416A1 (es) 2001-05-25
NO20022379D0 (no) 2002-05-16
DE60003072T2 (de) 2004-04-01
AU770045B2 (en) 2004-02-12
MXPA02005011A (es) 2003-10-14
BR0015613A (pt) 2002-07-23
ES2156574A1 (es) 2001-06-16
GEP20043240B (en) 2004-05-25
EA200200470A1 (ru) 2002-10-31
PT1231211E (pt) 2003-09-30
IS2014B (is) 2005-06-15
NZ519264A (en) 2003-10-31
CO5261560A1 (es) 2003-03-31
AR031080A1 (es) 2003-09-10
NO20022336L (no) 2002-07-09
IL149634A0 (en) 2002-11-10
ES2156574B1 (es) 2002-02-01
ES2199878T3 (es) 2004-03-01
HRP20020426A2 (en) 2004-02-29
DK1231211T3 (da) 2003-10-27
BG106699A (bg) 2003-02-28
EA004301B1 (ru) 2004-02-26
DE60003072D1 (de) 2003-07-03
CA2391913A1 (en) 2001-05-25
PL354877A1 (en) 2004-03-08
AU1281501A (en) 2001-05-30
CN1402724A (zh) 2003-03-12
IS6386A (is) 2002-05-15
HUP0203478A2 (hu) 2003-02-28
KR20020079737A (ko) 2002-10-19
AP2002002512A0 (en) 2002-06-30
CR6640A (es) 2004-03-05
EP1231211A1 (en) 2002-08-14
US7001910B1 (en) 2006-02-21
NO20022336D0 (no) 2002-05-15
ZA200203906B (en) 2004-03-26
CZ20021654A3 (cs) 2002-09-11
CN1159314C (zh) 2004-07-28
AP1330A (en) 2004-11-25
PE20010858A1 (es) 2001-08-22
SK6752002A3 (en) 2002-09-10
EP1231211B1 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
CA2474578A1 (en) Novel pyridin- and pyrimidin-derivatives
CA2368347A1 (en) Glucokinase activators
YU40202A (sh) Novi derivati tiazolidindiona kao antidijabetički agensi
WO2004101528A3 (en) Isoquinoline derivatives and their use as gfat inhibitors
WO2001012187A3 (en) Benzoic acid derivatives and their use as ppar receptor agonists
ATE427926T1 (de) Cycloalkylaminderivate
TWI265163B (en) Novel pyrido[2,1-a]isoquinoline derivatives
WO2005103037A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
AU2001284658A1 (en) Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TW200631580A (en) Substituted benzoquinolizine derivatives
UA86997C2 (ru) Производные антраниламида, пестицидная композиция на их основе и промежуточные соединения
DE50309979D1 (de) Neue purinderivate, deren herstelllung und deren verwendung als arzneimittel
RS93604A (en) Substituted phenylacetamides and their use as glucokinase activators
MXPA05013734A (es) Hexahidropiroisoquinolinas como inhibidores de dpp-iv.
MXPA04003759A (es) Derivados de pirrolidin n-substituido como inhibidores de dipeptidil peptidasa iv.
WO2004048345A3 (en) 2,5-diketopiperazines for the treatment of obesity
TW200626598A (en) Pyrrazolo-pyrimidine derivatives
WO2007015999A3 (en) Process for synthesizing a substituted pyrazole
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
WO2003048130A3 (en) Peroxisome proliferator activated receptor agonists
WO2004035800A3 (en) Intermediate cefdinir salts
WO2005077926A3 (en) Benzofuran and benzothiophene derivatives useful for the treatment of cardiovascular disease
MY140164A (en) Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same
NO20070974L (no) Substituerte N-acyl-2-aminotiazoler